In the Boardroom - Respiratory and Pulmonary


Current filters:

Respiratory and Pulmonary

Popular Filters

360 to 384 of 430 results

Aeras and CNBG in TB vaccine pact


The global fight against the tuberculosis epidemic has received a boost as USA-based Aeras and the China…

AeresBiotechnologyChina National BiotecPharmaceuticalResearchRespiratory and PulmonaryVaccines

Valeant ups its bid for ISTA Pharma


California, USA-based ophthalmology and allergy drug company ISTA Pharmaceuticals (Nasdaq: ISTA) says…

ISTA PharmaceuticalMergers & AcquisitionsOphthalmicsPharmaceuticalRespiratory and PulmonaryValeant Pharmaceuticals

GSK and Theravance to file COPD/asthma drug


UK pharma giant GlaxoSmithKline (LSE: GSK) and partner USA-based Theravance (Nasdaq: THRX), in which…

GlaxoSmithKlinePharmaceuticalRegulationRelovairResearchRespiratory and PulmonaryTheravance

Johnson & Johnson stops Doribax trial; reportedly agrees Risperdal settlement


The US Food and Drug Administration says that a recent clinical trial with Doribax (doripenem) being…

DoribaxFinancialJanssenJohnson & JohnsonLegalNeurologicalNorth AmericaPharmaceuticalResearchRespiratory and PulmonaryRisperdal

Takeda ends Daxas co-promotion with MSD; Actos law suits


Japan’s largest drugmaker, Takeda Pharmaceuticals (TYO: 4502) says that it has reached a mutual…

ActosDaxasDiabetesLegalLicensingMerck & CoNycomedPharmaceuticalRespiratory and PulmonaryTakeda Pharmaceuticals

AstraZeneca takes option on Prosidion diabetes assets; advances asthma drug


Looking to expand its R&D pipeline in the face of several recent product failures and facing a “patent…

DiabetesDynavax TechnologiesLicensingPharmaceuticalProsidionResearchRespiratory and Pulmonary

COPD market to grow to more than $13.4 billion in 2020


As a result of an expanding aging population, increases in drug treatment and the uptake of premium priced…

Boehringer IngelheimGlobalMarkets & MarketingolodaterolPharmaceuticalRespiratory and Pulmonarytiotropium

Germany’s IQWIG negative on InterMune’s Esbriet


US biotech firm InterMune (Nasdaq: ITMN) says that Germany’s private Institute for Quality and Efficiency…

BiotechnologyEsbrietEuropeInterMuneRare diseasesRegulationRespiratory and Pulmonary

NICE wants more data on Daxas


UK drugs watchdog the National Institute for Health and Clinical Excellence (NICE) has today issued final…

DaxasEuropeMerck & CoPharmaceuticalPricingRegulationRespiratory and Pulmonary

Theratechnologies to quit COPD program


Canada-based Theratechnologies (TSX: TH.TO) revealed yesterday that it is discontinuing its muscle wasting…

EgriftaFinancialNephrology and HepatologyPharmaceuticalResearchRespiratory and PulmonarytesamorelinTheratechnologies

MedicinesCo takes equity stake in GeNO, gaining access to nitric oxide platforms


USA-based The Medicines Company (Nasdaq: MDCO) says it has acquired a non-controlling equity investment…

GeNOLicensingMergers & AcquisitionsPharmaceuticalRespiratory and PulmonaryThe Medicines Company

South Africa debuts new five-year HIV and tuberculosis plan


Coinciding with Worlds AIDS day last week, the South African government launched its new national strategic…

Anti-viralsHealthcarePharmaceuticalRespiratory and PulmonaryRest of the World

Paladin gets certain rights to Immuron’s Travelan in up to C$117 million deal


Melbourne, Australia-based Immuron (ASX: IMC) and Canada’s Paladin Labs (TSX: PLB) have signed a…

Gastro-intestinalsImmuronLicensingPaladin LabsPharmaceuticalRespiratory and PulmonaryTravelan

New global data on influenza vaccine provision and level of support for immunization policies


The findings of two studies being published this week in peer-reviewed journals look at global vaccination…

GlobalHealthcarePharmaceuticalRespiratory and PulmonaryVaccines

Novartis and Vectura COPD drug candidate NVA237 filed for approval in Japan


The Japanese subsidiary of Swiss drug major Novartis (NOVO: VX) has filed an application for sales and…

Asia-PacificFinancialNovartisPharmaceuticalRegulationRespiratory and PulmonarySeebriVectura

Adeona Pharma and Intrexon collaborate for synthetic DNA-based PAH therapy


USA-based Adeona Pharmaceuticals (NYSE Amex: AEN) and the Human Therapeutics Division of Intrexon Corp…

Adeona PharmaCardio-vascularIntrexonLicensingPharmaceuticalResearchRespiratory and Pulmonary

Eisai in deal with Novartis to co-promote COPD drugs in Japan


Japanese drugmaker Eisai (TYO: 4523) has entered into a Japan co-promotion agreement with the local subsidiary…

Asia-PacificEisaiLicensingMarkets & MarketingNovartisOnbrezPharmaceuticalRespiratory and Pulmonary

Almirall starts Ph III COPD trial; collaborates with BioFocus; and posts sales and earnings downturn


There was a batch of news from Spain’s largest drugmaker Almirall (ALM. MC), starting with the announcement…

aclidiniumAlmirallFinancialForest LaboratoriesFormoterol Fumarate Inhalation PowderPharmaceuticalResearchRespiratory and Pulmonary

Faes Farma licences bilastine´s marketing rights in Indonesia to Kalbe


Spanish drugmaker Faes Farma has signed a licence agreement for the commercialization of its antihistamine…

Asia-PacificbilastineFaes FarmaKalbe PharmaLicensingPharmaceuticalRespiratory and Pulmonary

Skyepharma updates on Exparel, Flutiform and financial position


UK drug developer SkyePharma (LSE: SKP) yesterday issued an update on its R&D pipeline and provided an…

Anti-Arthritics/RheumaticsExparelFinancialFlutiformLodotraPharmaceuticalRegulationResearchRespiratory and PulmonarySkyepharma

Mylan to acquire Pfizer generic respiratory delivery platform; challenge to GSK


US generic drug major Mylan (Nasdaq: MYL) has entered into an agreement with global pharma behemoth Pfizer…

Advair DiskusGenericsGlaxoSmithKlineLicensingMylan LaboratoriesPfizerPharmaceuticalRespiratory and PulmonarySeretide

Vertex’ Kalydeco marks a milestone in fight against cystic fibrosis


The oral drug ivacaftor (VX-770) provides major, sustained improvement in lung function, growth and other…

ivacaftorKalydecoPharmaceuticalRare diseasesResearchRespiratory and PulmonaryVertex

Anti-inflammatory therapeutics market to grow to $85.9 billion in 2017


The anti-inflammatory therapeutics market accounted for $32.3 billion in 2002 from its seven major indications.…

Anti-Arthritics/RheumaticsGastro-intestinalsMarkets & MarketingNeurologicalPharmaceuticalRespiratory and Pulmonary

Vectura shares fall as partner Novartis reports US delay for lung cancer drug


Shares of UK-based Vectura (LSE: VEC) tumbled 22% at 66 pence on Tuesday, after the company revealed…

NovartisPharmaceuticalRegulationResearchRespiratory and PulmonarySeebriVectura

360 to 384 of 430 results

Back to top